Share
CNBC
Johnson & Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.
J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.
By Berkeley Lovelace Jr. | 13 Jan 2021
RELATED TOPICS:
Fresno Restaurateur Bobby Salazar Charged by Feds With Arson
2 hours ago
Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds
2 hours ago
US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says
2 hours ago
Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol
3 hours ago
HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials
3 hours ago
Valley Crime Stoppers’ Most Wanted Person of the Day: Enrique Arellano Ochoa
3 hours ago
Madera County Authorities Arrest Army Sergeant in Child Sexual Abuse Material Investigation
3 minutes ago
Categories

Madera County Authorities Arrest Army Sergeant in Child Sexual Abuse Material Investigation

Poll: Katie Porter Holds Early Edge in California Governor’s Race

Fresno Restaurateur Bobby Salazar Charged by Feds With Arson

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says
